Clinical trials: Gastrointestinal Neoplasms, open to volunteers
Gastrointestinal Malignancies
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for gastrointestinal malignancies.
- Trial name
- NCT06644274
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Gastrointestinal Neoplasm
Prospective Cohort Study on the Safety and Efficacy of Endorobotics for Endoscopic Submucosal Dissection (Endorobotics ESD)
This trial is a prospective, single arm study of 30 patients recruited to undergo endoscopic submucosal dissection (ESD) with a novel robotic assisted technology.
- Trial name
- NCT06726798
- Testing
- Endoscopic submucosal dissection with EndoRobotics traction device
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Liver Metastases, Colorectal Cancer
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
This is a Phase II study to determine the efficacy of SBRT to treat liver metastases in patients with Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors that are not amenable to…
- Conditions
- Liver Metastases, Colorectal Cancer, Anal Canal Cancer, Gastrointestinal Neuroendocrine Tumors
- Trial name
- NCT02185443
- Testing
- SBRT
- Where
- Brazil
- Volunteers
- 43 people
- Sponsor
- University of Sao Paulo
Gastrointestinal Malignancy
The 5-FU Holter Study
To assess the feasibility of using ambulatory ECG monitoring (Holter monitor) for patients receiving 5-FU chemotherapy
- Trial name
- NCT06538610
- Testing
- Holter monitor
- Where
- New Zealand
- Volunteers
- 10 people
- Sponsor
- University of Auckland, New Zealand
Digestive Cancers, Bile Duct Cancer
Spanish Registry of Digestive Tumours RETUD
The aim of this observational study is to assess the current state of digestive tumours in Spain. By doing so, it seeks to enhance the quality of care, optimize the diagnosis and treatment of digestive tumours, and identify…
- Conditions
- Digestive Cancers, Bile Duct Cancer, Hepatocellular Cancer (HCC), Colorectal Cancer (CRC)
- Trial name
- RETUD (NCT06711211)
- Where
- Spain
- Volunteers
- 20,000 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Gastrointestinal Cancer
JUMP_START - Optimization of Care for Young Cancer Patients with Gastrointestinal Tumors
JUMP_START aims to assess the needs of individuals aged ≤ 50 years with gastrointestinal (GI) tumors and implement a tailored support and counseling program at the University Hospital Heidelberg and the National Center for Tumor…
- Trial name
- JUMP_START (NCT06621277)
- Testing
- No intervention, Tailored counseling programs (Phase 2)
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- University Hospital Heidelberg
Cancer Gi
Prophylactic EUS-guided Gastroenterostomy in Advanced Periampullary Cancers
The goal of this randomized controlled trial is to investigate the effectiveness and safety of Prophylactic EUS-gastroenterostomy (ProEUS-GE) as a preventative approach for malignant gastric outlet obstruction (MGOO) in men and…
- Trial name
- INTERCEPT (NCT05994521)
- Testing
- ERCP alone, ERCP +ProEUS-GE
- Where
- 5 sites in Canada, France and 1 more
- Volunteers
- 110 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Gastrointestinal Neuroendocrine Pancreatic Tumor
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.
- Trial name
- NCT06505395
- Testing
- SYHX2008 injection, Sandostatin LAR@
- Where
- China
- Volunteers
- 90 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Gastrointestinal Cancer Metastatic
MAESTRO Study: Metabolic Imaging to Improve Patient-Specific Therapy Outcomes
Patients suffering metastasized gastrointestinal cancer often receive ineffective treatments for prolonged periods of time as therapy non-response, which is hard to detect, cannot be determined earlier than nine weeks following…
- Trial name
- MAESTRO (NCT04534543)
- Testing
- MRI/Spectroscopy
- Where
- 2 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Complication of Surgical Procedure, Infections
Pathogenesis of Postoperative Infections and Biomarkers for Early Diagnosis of it
Infections remain a prevalent complication after major abdominal surgery. The common belief that most surgical site infections (SSIs) following elective surgery with modern antiseptic techniques are due to intraoperative…
- Trial name
- NCT06513598
- Testing
- Major visceral surgery for gastrointestinal cancer
- Where
- 2 sites in Lithuania
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs.
- Conditions
- Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract, Neuroendocrine Neoplasm of Lung, Thymic Neuroendocrine Neoplasm
- Trial name
- NCT06523582
- Where
- 3 sites in Mexico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Gastrointestinal Stromal Tumors
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
The goal of this prospective study is to learn whether there is a synergistic effect when radiotherapy is combined with ripretinib in the treatment of patients with unresectable advanced GIST.
- Trial name
- NCT06507683
- Testing
- simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
General Anesthesia Gastrointestinal Cancer Surgery
The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study
The rapid progress of multiple antiemetic regimens ensures that patients can receive full dose chemotherapy, however, there are still a large number of unmet clinical needs in patient evaluation and treatment.
- Trial name
- NCT06417567
- Testing
- NEPA
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastrointestinal Tumors
BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors
This study is an exploratory single-arm, open, modified "3+3" dose escalation study with BGT007H injection. Approximately 11 to 14 subjects with recurrent/refractory gastrointestinal tumors will be enrolled to evaluate the safety…
- Trial name
- NCT06152757
- Testing
- First dose, Second dose, The third dose
- Where
- China
- Volunteers
- 14 people
- Sponsor
- BioSyngen Pte Ltd
Carcinoma, Gastrointestinal Diseases
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma.
- Conditions
- Carcinoma, Gastrointestinal Diseases, Stomach Cancer, Gastroesophageal-junction Cancer
- Trial name
- EXPLORING (NCT05494060)
- Testing
- Anlotinib hydrochloride capsule, Penpulimab Injection, XELOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastrointestinal Cancer
BGT007 Cells for the Treatment of Refractory Digestive System Tumors
This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007 injection in the treatment of recurrent/metastatic/refractory digestive system tumors
- Trial name
- NCT06104241
- Testing
- BGT007 Injection
- Where
- China
- Volunteers
- 14 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Gastrointestinal Neuroendocrine Carcinoma
First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma
First-Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma - a prospective Single-arm Phase II Study [NCT ID not yet assigned]
- Trial name
- NCT06070740
- Testing
- Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Peking Union Medical College Hospital
Gastrointestinal Neoplasm Malignant
Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models
This study will evaluate the utility of ChatGPT in recommending treatment plans for patients with gastrointestinal cancers, using both retrospective and prospective data.
- Trial name
- NCT06002425
- Testing
- Clinician-Directed Treatment Plan, ChatGPT-Assisted Treatment Plan
- Where
- 7 sites in United States, China and 2 more
- Volunteers
- 400 people
- Sponsor
- Chinese Academy of Sciences
Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
This is a 2 arms study concerning patients under imatinib treatment for at least 10 years of treatment with locally advanced/metastatic GIST. In the first arm, patients will discontinue Imatinib treatment.
- Conditions
- Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation, Advanced Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT05009927
- Testing
- Imatinib tablets
- Where
- 13 sites in France
- Volunteers
- 50 people
- Sponsor
- Centre Leon Berard
Gastrointestinal Stromal Tumor of Rectum
Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST
Prior to the implementation of preoperative imatinib mesylate therapy, a considerable percentage (ranging from 34.5% to 67.5%) of individuals diagnosed with rectal gastrointestinal stromal tumors (GIST) underwent abdominoperineal…
- Trial name
- PIRKER (NCT05970900)
- Testing
- Imatinib Mesylate, Local resection
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Fujian Medical University Union Hospital